Geneos Wealth Management Inc. Sells 195 Shares of Humana Inc. (NYSE:HUM)

Geneos Wealth Management Inc. trimmed its position in Humana Inc. (NYSE:HUM) by 31.4% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 427 shares of the insurance provider’s stock after selling 195 shares during the quarter. Geneos Wealth Management Inc.’s holdings in Humana were worth $195,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Gradient Investments LLC raised its position in shares of Humana by 200.0% during the fourth quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 40 shares during the period. Sunbelt Securities Inc. acquired a new position in Humana during the first quarter worth $28,000. Householder Group Estate & Retirement Specialist LLC bought a new position in shares of Humana in the third quarter valued at $39,000. Nvwm LLC grew its holdings in shares of Humana by 41.0% during the third quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock valued at $42,000 after buying an additional 25 shares during the last quarter. Finally, Turtle Creek Wealth Advisors LLC bought a new stake in shares of Humana during the fourth quarter worth about $55,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Humana

In other Humana news, Director Jorge S. Mesquita purchased 545 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The shares were bought at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the purchase, the director now owns 2,578 shares of the company’s stock, valued at approximately $946,358.02. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.32% of the company’s stock.

Humana Trading Down 1.2 %

NYSE:HUM opened at $312.59 on Monday. Humana Inc. has a 12 month low of $299.23 and a 12 month high of $541.21. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.63. The firm’s 50 day moving average is $347.21 and its 200 day moving average is $428.90. The stock has a market capitalization of $37.71 billion, a PE ratio of 15.77, a price-to-earnings-growth ratio of 1.83 and a beta of 0.45.

Humana (NYSE:HUM) last issued its earnings results on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.87). The firm had revenue of $26.46 billion during the quarter, compared to the consensus estimate of $25.47 billion. Humana had a net margin of 2.34% and a return on equity of 19.44%. The business’s quarterly revenue was up 17.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.62 earnings per share. Sell-side analysts expect that Humana Inc. will post 16.06 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Friday, March 29th will be given a dividend of $0.885 per share. The ex-dividend date is Wednesday, March 27th. This represents a $3.54 dividend on an annualized basis and a yield of 1.13%. Humana’s dividend payout ratio is presently 17.86%.

Analyst Ratings Changes

A number of research firms have issued reports on HUM. Royal Bank of Canada cut their price target on Humana from $507.00 to $415.00 and set an “outperform” rating for the company in a research note on Friday, January 26th. Mizuho decreased their price target on Humana from $550.00 to $400.00 and set a “buy” rating for the company in a report on Friday, January 26th. UBS Group restated a “neutral” rating and set a $370.00 price objective (down from $530.00) on shares of Humana in a research note on Friday, January 26th. Wells Fargo & Company reduced their target price on shares of Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a research note on Monday, April 8th. Finally, TD Cowen dropped their price target on shares of Humana from $427.00 to $396.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Eleven research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $465.42.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.